EZH2和p53蛋白在前列腺癌中的表达及其临床意义

 【摘要】　目的　探讨EZH2和p53蛋白在前列腺癌组织中的表达及其临床意义。方法　通过组织芯片技术，应用EnVision免疫组织化学法检测48例术前无放化疗史的前列腺癌标本和15例良性前列腺增生组织中EZH2、p53蛋白的表达情况，并分析EZH2和p53蛋白在前列腺癌组织中的表达与临床病理特征关系以及两者间的相关性。结果　前列腺癌组织中EZH2和p53蛋白的阳性表达率分别为87.50 %（42／48）和33.33 %（16／48），明显高于良性前列腺增生组织13.33 %（2／15）和0（0／15）（χ2＝26.429、χ2＝5.058，均P＜O.05）；EZH2和p53蛋白在前列腺癌中的表达均与Gleason分级、TNM分期相关（P＜0.05），与患者年龄、前列腺特异性抗原（PSA）水平无关（P＞0.05）。在Gleason分级中，Gleason＞6分组阳性表达率高于Gleason≤6分组；TNM分期中，T3～T4期阳性表达率高于T1～T2期。Spearman等级相关分析显示，前列腺癌组织中EZH2和p53蛋白的表达呈正相关性（r＝0.294，P＜0.05）。结论　EZH2和p53可能共同参与了前列腺癌的发生、发展过程，联合检测EZH2和p53蛋白有望成为预测前列腺癌恶性程度进展的参考指标。同时也可能为临床治疗前列腺癌提供新的理论依据。

Expression and clinical significance of EZH2 and p53 protein in human prostate cancer

Objective To explore the expression of EZH2 and p53 protein in primary prostate cancer (Pca) and its clinical significance.Methods High-throughput tissue microarray technique and immunohistochemistry was used to detect the expression of EZH2 and p53 protein in 48 human prostate cancer specimens without a history of chemo-radiation therapy and 15 cases of benign prostate hyperplasic (BPH) tissues. The pathological characteristics and the relationship of the expression of EZH2 and p53 protein in primary prostate cancer was analyzed. Results Immunohistochemical results showed that the positive rates of EZH2 and p53 protein in prostate cancer were 87.50 ％ (42/48) and 33.33 ％ (16/48), respectively, which were significantly higher than that in BPH tissues[13.33 ％ (2/15) and 0 (0/15)](x2=26.429, x2=5.058,P ＜0.05). The expression of EZH2 and p53 protein was significantly related to Gleason score, TNM stage (P ＜0.05), but not to age and serum prostate-specific antigen (PSA) level (P ＞0.05). The positive expression in patients with Gleason＞6 was higher than that with Gleason≤6 (P ＜0.05). The positive expression in patients with T3-T4 stage was higher than that with T1-T2 stage (P ＜0.05). Spearman rank correlation showed a significantly positive correlation between EZH2 and p53 protein (r=0.294, P ＜0.05). Conclusion EZH2 and p53 protein may participate in the pathogenesis of prostate cancer. The overexpression of EZH2 and p53 protein could become an index for the evaluation of the level of malignancy and progression of prostate cancer.Furthermore, combining detection of EZH2 and p53 protein may provide a new theoretical basis for the treatment of prostate cancer.